2020 Year in Review: Amyloidosis

Atrial Fibrillation and Stroke Burden: A Comparison of African American and Caucasian Patients with Transthyretin Cardiac Amyloidosis

ATTR-CM

Despite similar rates of major bleed and stroke among African American and Caucasian patients with transthyretin cardiac amyloidosis, African American patients present with fewer cases of atrial fibrillation. Read More ›

Conclusive Diagnosis of Transthyretin Cardiac Amyloidosis Is Dependent on Ruling Out Light Chain Amyloidosis

ATTR-CM

In a retrospective analysis at a single center, 15% of patients with light chain amyloidosis cardiomyopathy had significant myocardial uptake on a 99mTc-PYP scan. Read More ›

Functional Class and Biomarker Stability in Patients Treated with Tafamidis for Transthyretin Cardiac Amyloidosis

ATTR-CM

Tafamidis-treated ATTR-CM patients observed stable functional status and biomarkers, despite a higher proportion of worse NYHA functional class in this real-world population. Read More ›

Registry Evaluation Provides Insights into Rhythmic Disturbances of Patients with Cardiac Amyloidosis and Implantation of Cardiac Electronic Devices

ATTR-CM

Both atrial and ventricular arrhythmias are common manifestations of cardiac amyloidosis, frequently necessitating implantation of cardiac electronic devices. Read More ›

Phenotypic Sex Differences in Transthyretin Amyloidosis V122I Mutation Patients

ATTR-CM

Female ATTR V122I patients present predominantly with polyneuropathy phenotype at a younger age, while males present with predominantly cardiovascular or mixed phenotype. Read More ›

Impact of Tc-99m Pyrophosphate Scan on Workflow When Diagnosing Cardiac Amyloidosis

ATTR-CM

Internal quality control and continued education for technologists and readers of PYP scans are important to avoid misdiagnosis. A standardized protocol for evaluation of cardiac amyloidosis could help eliminate variability in testing patterns. Read More ›

Prevalence and Predictors of Transthyretin Amyloidosis in Patients Who Underwent Transcatheter Aortic Valve Implantation

Screening for ATTR-CA should be considered in patients with aortic stenosis undergoing transcatheter aortic valve implantation. Read More ›

Transcatheter Aortic Valve Replacement is Appropriate for Patients with Aortic Stenosis and Cardiac Amyloidosis

ATTR-CM

Based on data from 3 international sites, transcatheter aortic valve replacement should not be withheld in patients with both aortic stenosis and cardiac amyloidosis. Read More ›

Complete Stabilization of Transthyretin by Acoramidis

ATTR-CM

Acoramidis (AG10) displays differential TTR binding, kinetic stability, and a higher degree of stabilization compared with tafamidis. Read More ›

Evaluation of Acoramidis (AG10) in Patients with ATTR-CM in a Phase 3 Randomized, Double-Blind, Placebo-Controlled Clinical Trial: The ATTRibute-CM Study Design

ATTR-CM

ATTRibute-CM is designed to evaluate the ability of acoramidis (AG10) to slow or halt progression of ATTR-CM. Read More ›